Jelly Roll is setting the record straight on his weight loss, and exactly how it came to be
In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
Romero-Gmez, M., Zelber-Sagi, S
But the states two biggest insurers, Blue Cross Blue Shield of Massachusetts and Point32Health, the owner of Harvard Pilgrim and Tufts Health Plan, are ending coverage of GLP-1 drugs for weight loss next year because of spiraling costs
Because these are just people reporting the side effects associated with losing weight
It is safe and effective